PEGylation technology from ALL Chemistry
ALL Chemistry Inc. offers a full range of PEGylation services to researchers and discovery-stage companies in need of high quality services. Our experienced team of experts are here to help you in both the discovery and development of your therapeutic protein.
PEGylation technology refers to the process of modifying a molecule, typically a protein or peptide, by attaching polyethylene glycol (PEG) chains to its surface. This innovative approach has been widely adopted in the pharmaceutical industry to improve the pharmacokinetic and pharmacodynamic properties of drugs, and has proven to be a valuable tool in drug development.
The PEGylation process involves covalently attaching PEG chains to the surface of a protein or peptide. PEG is a biocompatible and water-soluble polymer that is widely used in the pharmaceutical industry due to its ability to improve the solubility, stability, and half-life of drugs. By attaching PEG chains to a protein or peptide, the resulting PEGylated molecule is able to resist degradation and clearance by the body, resulting in a longer half-life and increased bioavailability.
One of the key benefits of PEGylation technology is its ability to improve the safety and efficacy of drugs. By increasing the half-life of a drug, PEGylation can reduce the frequency of dosing and the likelihood of adverse effects, making drugs more tolerable for patients. PEGylation can also improve the stability of drugs, making them more resistant to degradation and ensuring consistent dosing.
PEGylation has been used to improve the properties of a wide range of drugs, including enzymes, antibodies, and small molecules. For example, PEGylated interferon has been used to treat hepatitis C by reducing the frequency of dosing and improving patient tolerability. PEGylated liposomes have been used to improve the delivery of anticancer drugs, increasing their accumulation in tumors and reducing side effects. PEGylated insulin has been used to improve the pharmacokinetics of insulin therapy, reducing the frequency of dosing and improving patient compliance.
Despite the many benefits of PEGylation technology, there are some limitations to its use. One of the main limitations is the potential for immunogenicity, or the development of an immune response to the PEGylated molecule. This can be mitigated by carefully selecting the size and structure of the PEG chain, and by conducting thorough preclinical studies to assess the potential for immunogenicity.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance